Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics approved special retention and change-in-control protections for its remaining leadership after a major restructuring tied to ending development of pociredir for sickle cell disease. The compensation committee granted cash retention bonuses to nine remaining full-time employees, including top executives.
President and CEO Alex C. Sapir will receive $370,040, and Chief Legal Officer Curtis Oltmans and Chief Financial Officer Alan Musso will receive $195,480 and $195,200, respectively, payable in cash if there is a qualifying change in control or a termination without cause, subject to completion of transitional duties. Their employment agreements were amended to align retention payments with incremental change-in-control benefits.
The company also extended change-in-control benefits to remaining employees at the Vice President level and above on similar terms. Separately, Fulcrum disclosed that Vice President, Finance and principal accounting officer Greg Tourangeau will depart on a mutually agreed future date, and stated his departure is not due to any disagreement regarding financial reporting or controls.
Fulcrum Therapeutics, Inc. Schedule 13G: Tang-linked holders report 5,451,800 shares (8.2%). Tang Capital Management, Kevin Tang and affiliated Tang Capital entities report shared voting and dispositive power over 5,451,800 shares of Common Stock. The filing bases the percentage on 66,633,321 shares outstanding as of April 20, 2026 per the company's Form 10-Q.
The statement identifies the filing parties, their addresses, and citizenship; it lists shared voting/dispositive power across Tang Capital Partners entities and confirms signatures by Kevin Tang on June 10, 2026.
Fulcrum Therapeutics is undertaking a major restructuring after discontinuing development of pociredir for sickle cell disease. The board approved a plan that cuts the workforce by about 85%, reducing headcount from 57 to 9 full-time employees, with the changes expected to be largely complete in the second quarter of 2026.
The company expects approximately $4.2 million in charges tied mainly to severance, benefits and related costs, most of which will require future cash payments during the same quarter. Fulcrum is also conducting a broad review of strategic alternatives and has hired Leerink Partners LLC to advise on potential transactions such as mergers, acquisitions, or asset sales, though there is no assurance that any deal will occur.
Fulcrum Therapeutics has discontinued development of pociredir, its lead program for sickle cell disease, after FDA feedback left no viable regulatory path forward. The FDA cited malignancy risks associated with PRC2 inhibition, referencing secondary hematologic cancers seen with the PRC2 inhibitor Tazverik, which was withdrawn globally in March 2026.
At the same time, Fulcrum has begun a comprehensive review of strategic alternatives, which may include a merger, acquisition, business combination, or other strategic transactions involving the company or its assets. The company is also taking steps to significantly reduce operating expenses and preserve capital. As of March 31, 2026, Fulcrum held $333.3 million in cash, cash equivalents, and marketable securities.
THERAPEUTICS, INC. reports that Nantahala Capital Management, LLC and two affiliated reporting persons together beneficially own 3,050,040 shares of Common Stock.
As of March 31, 2026 the filing states those shares represent 4.58% of the class. The filing lists shared voting and dispositive power over the 3,050,040 shares and notes Messrs. Wilmot B. Harkey and Daniel Mack are filing as control persons in respect of shares held by Nantahala. Signatures are dated May 15, 2026.
Fulcrum Therapeutics files Amendment No. 1 to a previously submitted Schedule 13G, reporting shared voting and dispositive power over 5,250,000 shares of Common Stock. The amendment states this equals 7.9% of the class based on 66,633,321 shares outstanding as of April 20, 2026, and attributes the holdings to TCG Crossover II, its general partner TCG Crossover GP II, and Chen Yu.
The filing clarifies ownership chains and disclaims group status; it amends the original statement filed September 20, 2024, and attaches the joint-filing agreement referenced in the original.
Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer received a grant of stock options covering 64,000 shares of common stock. The options have an exercise price of $8.08 per share and are scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.
Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer filed an initial ownership report indicating that he currently holds no company securities. The filing shows zero shares directly owned following the reported holding entry, meaning he reports no beneficial ownership of Fulcrum Therapeutics stock at this time.
Fulcrum Therapeutics, Inc. will hold a virtual 2026 annual meeting on June 24, 2026 at 9:00 a.m. Eastern, where stockholders will vote on electing three Class I directors, a non-binding advisory vote on executive compensation, and ratifying Ernst & Young LLP as auditor.
Stockholders of record at the close of business on April 27, 2026, when 66,633,321 shares of common stock were outstanding, may vote online, by phone, mail, or during the virtual meeting. In 2025, Fulcrum reported a net loss of $74.9 million and completed a public equity offering raising $164.2 million of net proceeds, while CEO Alex Sapir received total compensation of $3.25 million.